Excessive daytime sleepiness in psychiatry: A relevant focus for clinical attention and treatment?

International Journal of Psychiatry in Clinical Practice

Volumn 10, Issue 2, 2006, Pages 117-123

  Hawley, Chris ^a,b  

^a QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Excessive daytime sleepiness; Excessive sleepiness; Hypersomnia; Modafinil; Psychiatry; Somnolence

Indexed keywords

DEXAMPHETAMINE; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; NEUROLEPTIC AGENT; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL TRIAL; COGNITION; DAYTIME SOMNOLENCE; DEPRESSION; DRUG ABUSE; DRUG DEPENDENCE; HALLUCINATION; HUMAN; INSOMNIA; MAJOR DEPRESSION; MENTAL DISEASE; MENTAL PATIENT; NARCOLEPSY; POLYSOMNOGRAPHY; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCREENING; SEDATION; SIDE EFFECT; SLEEP WAKING CYCLE; SOMNOLENCE; WAKEFULNESS;

EID: 33745067507     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500600578904     Document Type: Article

References (64)

1. Tandberg E, Jan P, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: A community-based study. Move Disord 1999;14(6):922-7.
2. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001;57(8):1392-6.
3. Rubinsztein JS, Rubinsztein DC, Goodburn S, Holland AJ. Apathy and hypersomnia are common features of myotonic dystrophy. J Neurol Neurosurg Psychiatry 1998;64:510-5.
4. Sforza E, Haba-Rubio J, De Bilbao F, Rochat T, Ibanez V. Performance vigilance task and sleepiness in patients with sleep-disordered breathing. Eur Resp J 2004;24(2):279-85.
5. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase-2 study. J Neurol Neurosurg Psychiatry 2002;72(2):179-83.
6. Ohayon MM, Caulet M, Philip P, et al. How sleep and mental disorders are related to complaints of daytime sleepines. Arch Intern Med 1997;157:2645-52.
7. Brassington GS, King AC, Bliwise DL. Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64-99 years. J Am Geriatr Soc 2000;48:1234-40.
8. Ohayon MM, Vecchierini MF. Daytime sleepiness and cognitive impairment in the elderly population. Arch Intern Med 2002;162:201-8.
9. Foley D, Monjan A, Masaki K, Ross W, Havlik R, White L, Launder L. Daytime sleepiness is associated with 3-year incident dementia and cognitive decline in older Japanese-American men. J Am Geriatr Soc 2001;48:1628-32.
10. MacDonald JR, Hill JD, Tamopolsky MA. Modafinil reduces somnolence and enhances mood in patients with myotonic muscular dystrophy. Neurology 2002;59:1876-80.
11. Talbot K, Stradling J, Crosby J, Hilton-Jones D. Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy. Neuromusc Disord 2003;13:357-64.
12. US Modafinil in Narcolepsy Multi-center Study Group. Randomized trial of modafinil for the treatment of pathologic somnolence in narcolepsy. Ann Neurol 1998;43:88-97.
13. US Modafinil in Narcolepsy Multi-center Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-75.
14. Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep 2005;8:1-8.
15. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002;72:179-83.
16. Johns MW. A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep 1991;14(6):540-5.
17. Mahowald MW. What is causing excessive daytime sleepiness? Evaluation to distinguish sleep deprivation from sleep disorders. Postgrad Med 2000;107(3):108-23.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association.
19. National Library of Medicine Dictionary of Terms: www.nim.nih.gov/ medlineplvs
20. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, Keenan S. Guidelines for the multiple sleep latency test (MSLT): A standard measure of sleepiness. Sleep 1986;9:519-24.
21. Mitler MM, Gujavarty KS, Browman CP. Maintenance of wakefulness test: A polysomnographic technique for evaluation treatment efficacy in patients with excessive somnolence. Electroencephalogr Clin Neurophysiol 1982;53:658-61.
22. Johns MW. Sleepiness in different situations masured by the Epworth Slepiness Scale. Sleep 1994;17(8):703-10.
23. Hoddes E, Dement W, Zarcone V. The development and use of the Stanford Sleepiness Scale (SSS). Psychophysiology 1972;9:150.
24. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: A new approach. Psychophysiology 1973;10:431-6.
25. Cook Y, Schmitt F, Berry D, Gilmore R, Phillips B, Lamb D. The effects of nocturnal sleep, sleep-disordered breathing and periodic movements of sleep on the objective and subjective assessment of daytime somnolence in healthy aged adults. Sleep Res 1988;17:95.
26. Chervin RD, Aldrich MS, Picket R, Guilleminault C. Comparison of the results of the Epworth Sleepiness Scale and the Multiple Sleep Latency Test. J Psychosom Res 1997;42(2):145-55.
27. Nofzinger EA, Thase ME, Reynolds 3rd CF, Himmelhoch JM, Mallinger A, Houck P, Kupfer DJ. Hypersomnia in bipolar depression: a comparison with narcolepsy using the multiple sleep latency test. Am J Psychiatry 1991;148(9):1177-81.
28. Parker G, Roy K, Mitchell P, Wilhelm K, Malhi G, Hadzi-Pavlovic D. Atypical depression: A reappraisal. Am J Psychiatry 2002;159:1470-9.
29. Hublin C, Kaprio J, Partinen M, Heikkila K, Koskenvuo M. Daytime sleepiness in an adult Finnish population. J Internal Med 1996;239:417-23.
30. Hara C, Lopes Rocha F, Lima-Costa MF. Prevalence of excessive sleepiness and associated factors in a Brazilian community: The Bambui study. Sleep Med 2004;5(1):31-6.
31. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's Disease: A community-based study. Move Disord 1999;14(6):922-7.
32. Horwath E, Johnson J, Weissman MM, Hornig CD. The validity of major depression with atypical features based upon a community study. J Affect Disord 1992;26:117-25.
33. Matza LS, Revicki DA, Davidson JR, Stewart JW. Depression with atypical features in the National Comorbidity Survey: classification, description, and consequences. Arch Gen Psychiatry 2003;60(8):817-26.
34. Lundt L. Use of the Epworth Sleepiness Scale to evaluate the symptom of excessive sleepiness in major depressive disorder. Gen Hosp Psychiatry 2005;27:146-8.
35. Monti JM, Monti D. Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Med Rev 2004;8(2):133-48.
36. Beasley CM Jr, Koke SC, Nilsson ME, Gonzales JS. Adverse events and treatment discontinuations in clinical trials of Fluoxetine in major depressive disorder: An updated meta-analysis. Clin Ther 2000;22(11):1319-30.
37. Dunbar GC, Cohn JB, Fabre LF, Feighner JP, Fieve RR, Mendels J, Shrivastava RK. A comparison of paroxetine, imipramine and placebo in depressed outpatients. Br J Psychiatry 1991;159:394-8.
38. Mendels J, Kiev A, Fabre LF. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depression Anxiety 1999;9:54-60.
39. Lydiard RRB, Stahl S, Hertzman M, Harrison WM. A double-blind, placebo controlled study comparing the effects of sertraline versus amitryptyline in the treatment of major depression. J. Clin Psychiatry 1997;58(11):484-91.
40. Stahl S. Optimizing wakefulness in patients with fatigue and executive dysfunction. J Clin Psychiatry 2003;64(Suppl 14):3-4.
41. Fava M. Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. J Clin Psychiatry 2003;64(Suppl 14):30-4.
42. Feighner JP, Boyer WF. Paroxetine in the treatment of depression: A comparison with imipramine and placebo. J Clin Psychiatry 1992;53(Suppl 2):44-7.
43. Doogan DP, Langdon CJ. A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. Int Clin Psychopharmacol 1994;9:95-100.
44. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and Haloperidol: Acute phase results of the North American double-blind trial. Neuropsychopharmacology 1996;14(2):113-23.
45. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ; Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 2001;49:52-63.
46. Bitter I, Dossenbach MRK, Brook S, Feldman PD, Metcalfe S, et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 2004;28:173-80.
47. Azorin JM, Spiegel R, Remington G, Vanelle JM, Pere JJ, Giguere M, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 2001;158:1305-13.
48. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Res 2003;61:123-36.
49. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001;23(11):1839-54.
50. Levoyer D, Martinet JP, Badiche A, Millet B. Ten years of clinical experience with clozapine about 170 patients. Encephale 2004;30(3):285-95.
51. Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker WW. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002;63(1):49-53.
52. Hartmann E, Orzack MH, Branconnier R. Sleep deprivation deficits and their reversal by d- and 1- amphetamine. Psychopharmacology 1977;53(2):185-9.
53. Koelega HS. Stimulant drugs and vigilance performance: A review. Psychopharmacology 1993;111(1):1-16.
54. Burke M, Sebastian CS. Treatment of clozapine sedation (letter). Am J Psychiatry 1993;150:1900-1.
55. Rosenthal MH, Bryant SL. Benefits of adjunct modafinil in a open-label, pilot study in patients with schizophrenia. Clin Neuropharmacol 2004;27(1):38-43.
56. Fava M, Thase ME, DeBattista C. A multi-center, placebo-controlled study of Modafinil augmentation in SSRI partial responders with persistent fatigue and sleepiness. J Clin Psychiatry 2005;66(1):85-93.
57. Schwartz TL, Azhar N, Cole K, Hopkins G, Nihalani N, Simionescu M, et al. An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. J Clin Psychiatry 2004;65(9):1223-7.
58. Schwartz TL, Azhar N, Cole K, Hopkins G, Nihalani N, Simionescu M, et al. An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. J Clin Psychiatry 2004;65(9):1223-7.
59. De Battista C, Lembke A, Solvason HB, Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacology 2004;24(1):87-90.
60. Ninan PT, Hassman HA, Glass SJ, McManus FC. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. J Clin Psychiatry 2004;65(3):414-20.
61. DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR. Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: A preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003;64(9):1057-64.
62. Markovitz PJ. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy. J Clin Psychopharmacol 2003;23(2):207-9.
63. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000;61(5):378-81.
64. Miletin MS, Hanly PJ. Measurement properties of the Epworth sleepiness scale. Sleep Med 2003;4:195-9.